Anis A - Search Results

1

Cost-effectiveness analysis of potential improvements to emergency medical services for victims of out-of-hospital cardiac arrest.

Nichol G, Laupacis A, Stiell IG, O'Rourke K, Anis A, Bolley H, Detsky AS. Nichol G, et al. Among authors: anis a. Ann Emerg Med. 1996 Jun;27(6):711-20. doi: 10.1016/s0196-0644(96)70188-9. Ann Emerg Med. 1996. PMID: 8644957

2

Cost-effectiveness analysis of the Ottawa Ankle Rules.

Anis AH, Stiell IG, Stewart DG, Laupacis A. Anis AH, et al. Ann Emerg Med. 1995 Oct;26(4):422-8. doi: 10.1016/s0196-0644(95)70108-7. Ann Emerg Med. 1995. PMID: 7574122

3

Using the Ottawa Ankle Rules.

Laupacis A, Stiell I, Stewart D, Anis A. Laupacis A, et al. Among authors: anis a. Ann Emerg Med. 1996 Dec;28(6):730-1. doi: 10.1016/s0196-0644(96)70102-6. Ann Emerg Med. 1996. PMID: 8953973 No abstract available.

4

A cost effectiveness analysis of cyclosporine in rheumatoid arthritis.

Anis AH, Tugwell PX, Wells GA, Stewart DG. Anis AH, et al. J Rheumatol. 1996 Apr;23(4):609-16. J Rheumatol. 1996. PMID: 8730113

5

Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.

Bansback N, Phibbs CS, Sun H, O'Dell JR, Brophy M, Keystone EC, Leatherman S, Mikuls TR, Anis AH; CSP 551 RACAT Investigators. Bansback N, et al. Ann Intern Med. 2017 Jul 4;167(1):8-16. doi: 10.7326/M16-0713. Epub 2017 May 30. Ann Intern Med. 2017. PMID: 28554192

6

A cost-effectiveness analysis of propofol versus midazolam for procedural sedation in the emergency department.

Hohl CM, Nosyk B, Sadatsafavi M, Anis AH. Hohl CM, et al. Acad Emerg Med. 2008 Jan;15(1):32-9. doi: 10.1111/j.1553-2712.2007.00023.x. Acad Emerg Med. 2008. PMID: 18211311 Free article.

7

Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents.

Singh S, Sun H, Anis AH. Singh S, et al. J Rheumatol. 2004 Aug;31(8):1607-13. J Rheumatol. 2004. PMID: 15290742

8

Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.

Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, White M, Sizto S, Liang MH. Finckh A, et al. Among authors: anis ah. Ann Intern Med. 2009 Nov 3;151(9):612-21. doi: 10.7326/0003-4819-151-9-200911030-00006. Ann Intern Med. 2009. PMID: 19884622

9

Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia.

Wong CL, Bansback N, Lee PE, Anis AH. Wong CL, et al. Can J Neurol Sci. 2009 Nov;36(6):735-9. doi: 10.1017/s0317167100008350. Can J Neurol Sci. 2009. PMID: 19960752

10

Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.

Marra CA, Esdaile JM, Anis AH. Marra CA, et al. Among authors: anis ah. J Rheumatol. 2002 Dec;29(12):2507-12. J Rheumatol. 2002. PMID: 12465143

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

357 results

Search Page

Filters